
|Articles|September 15, 2002
Clinical setting may not reflect phase III glaucoma trials
Philadelphia-The performance of glaucoma medications in phase III FDA trials may not reflect their performance in a real-world clinical setting, according to researchers at Wills Eye Hospital.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Phase 3 NORTHSTAR Trial Launches for Gildeuretinol in Stargardt Disease
2
Rising Star: Introducing Viha Vig, MBChB
3
Self-Screening for Ocular Surface Malignancies Using a Smartphone
4
Everest Medicines acquires Greater China rights to Aceclidine Presbyopia Eye Drop (VIZZ)
5





















